This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
May 20, 2013 /PRNewswire/ -- Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing potential best-in-class oncology therapies announced today that Dr.
Peter Suzdak, CEO of Rexahn, will present at the Second Annual Marcum LLP MicroCap Conference on
Thursday, May 30, 2013 in
New York City at the Grand Hyatt Hotel.
The Company's presentation is scheduled to begin at
10:30 AM EDT.
For more information and registration, please visit the conference website:
http://www.marcumllp.com/microcapAbout Rexahn Pharmaceuticals, Inc.Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin
®, RX-3117, and RX-5902 and a robust pipeline of preclinical compounds to treat multiple types of cancer. Rexahn has also developed proprietary drug discovery platform technologies in the areas of nano-medicines, 3D-GOLD, and TIMES. For more information, please visit
About Marcum LLP
Marcum LLP is one of the largest independent public accounting and advisory services firms in the nation. Ranked among the top 15, Marcum LLP offers the resources of 1,000 professionals, including over 125 partners, in more than 20 offices throughout
Grand Cayman and
China. Headquartered in
New York City, the Firm's presence runs deep with full-service offices strategically located in major business markets. Marcum is a member of the
Marcum Group, an organization providing a comprehensive range of professional services spanning accounting and advisory, technology solutions, wealth management, and executive and professional recruiting. The Marcum Group companies include
Marcum Technology LLC;
Marcum Search LLC;
Marcum Financial Services LLC;
Marcum Bernstein & Pinchuk LLP;
MarcumBuchanan Associates LLC; and
Marcum Cronus Partners LLC.Tricia SwansonThe Trout Group LLC
SOURCE Marcum LLP